Goldman Sachs’s TRIUS THERAPEUTICS INC COM STK (DE) TSRX Stock Holding History

Goldman Sachs’s Portfolio TSRX Stock Details TSRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-14,848	Closed	-$120K	–	6876
2013 Q2	$120K	Buy	+14,848	New	+$110K	﹤0.01%	5818

Other funds holding TSRX

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

FCH

Freestone Capital Holdings Seattle, Washington $3.3B AUM 21.14% 1-Year Est. Return

Amici Capital New York $257M AUM 4.88% 1-Year Est. Return

FWM

Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Goldman Sachs's TSRX Position: Q3 2013 in Review

Goldman Sachs sold out of TRIUS THERAPEUTICS INC COM STK (DE) (TSRX) in Q3 2013, closing a stake of 14,848 shares — an estimated $120K sold.

Goldman Sachs first reported a position in TSRX in Q2 2013 and held it in 1 quarter. The position peaked at $120K in Q2 2013. 7 funds tracked by Wall St. Rank hold TSRX as of Q3 2013.

Goldman Sachs reported no remaining TRIUS THERAPEUTICS INC COM STK (DE) position as of Q3 2013 after selling out during the quarter.
Goldman Sachs sold 14,848 TRIUS THERAPEUTICS INC COM STK (DE) shares in Q3 2013, an estimated $120K.
Goldman Sachs first reported a position in TRIUS THERAPEUTICS INC COM STK (DE) in Q2 2013 and held it in 1 quarter.
Goldman Sachs's TRIUS THERAPEUTICS INC COM STK (DE) position peaked at $120K in Q2 2013.
7 funds tracked by Wall St. Rank held TRIUS THERAPEUTICS INC COM STK (DE) as of Q3 2013.

Based on Goldman Sachs's 13F filing for Q3 2013, filed 14 Nov 2013.